Comparative Pharmacology
Head-to-head clinical analysis: CHLOROMYXIN versus PROLOPRIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLOROMYXIN versus PROLOPRIM.
CHLOROMYXIN vs PROLOPRIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chloromyxin is a combination product of chloramphenicol and polymyxin B. Chloramphenicol inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing peptide bond formation. Polymyxin B disrupts bacterial cell membrane integrity by interacting with lipopolysaccharides in gram-negative bacteria.
Inhibits bacterial dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolic acid to tetrahydrofolic acid, thereby inhibiting bacterial DNA, RNA, and protein synthesis.
500 mg IV every 6 hours or 1 g IV every 12 hours; infusion over 30 minutes.
100 mg orally twice daily or 200 mg orally once daily.
None Documented
None Documented
CHLOROMYXIN is not a recognized drug. No data available.
Terminal elimination half-life is 8-10 hours in normal renal function; prolonged (>20 hours) in significant renal impairment.
CHLOROMYXIN is not a recognized drug. No data available.
Primarily renal (80-90% as unchanged drug); less than 5% as metabolites; fecal excretion negligible.
Category C
Category C
Antibiotic
Antibiotic